Quanterix (NASDAQ:QTRX) Rating Lowered to Sell at Wall Street Zen

Quanterix (NASDAQ:QTRX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other brokerages also recently issued reports on QTRX. Canaccord Genuity Group upped their price target on shares of Quanterix from $5.00 to $8.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Quanterix has an average rating of “Reduce” and a consensus target price of $8.00.

Quanterix Price Performance

QTRX stock opened at $3.50 on Friday. The business has a fifty day moving average price of $4.75 and a 200 day moving average price of $5.83. Quanterix has a fifty-two week low of $3.23 and a fifty-two week high of $8.77. The stock has a market capitalization of $164.29 million, a price-to-earnings ratio of -1.39 and a beta of 1.32.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). The business had revenue of $41.40 million during the quarter, compared to analyst estimates of $37.95 million. Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%. On average, equities analysts expect that Quanterix will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quanterix

A number of hedge funds and other institutional investors have recently bought and sold shares of QTRX. Royal Bank of Canada boosted its stake in Quanterix by 26.3% in the first quarter. Royal Bank of Canada now owns 170,745 shares of the company’s stock valued at $1,112,000 after acquiring an additional 35,509 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Quanterix by 204.4% during the 1st quarter. AQR Capital Management LLC now owns 98,990 shares of the company’s stock valued at $644,000 after acquiring an additional 66,470 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Quanterix by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company’s stock valued at $2,277,000 after purchasing an additional 59,655 shares during the period. Jane Street Group LLC boosted its position in shares of Quanterix by 4.2% in the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock worth $380,000 after purchasing an additional 2,366 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Quanterix by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 887,080 shares of the company’s stock worth $5,900,000 after purchasing an additional 21,210 shares during the last quarter. 86.48% of the stock is owned by institutional investors.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.